Buy Strides Pharma Sciences, target of Rs 450: Sharekhan

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Sharekhan's research report on Strides Pharma Sciences

Strides Pharma Sciences (Strides) posted strong numbers in Q3FY2023 with the fifth consecutive quarter of a sequential improvement in EBITDA margins to 13.5% from 0.6% in Q3FY2022. Revenues grew by 8.9% y-o-y to Rs. 864.8 crore; adjusted PAT stood at Rs. 61.3 crore. US business continued to grow at a strong rate in Q3FY2023, since Q1FY2023. The company management is hopeful of reaching to pre-COVID EBITDA margins in the short term.

Outlook

The stock has corrected by ~16% over the last one year and is trading at a reasonable valuations of 11.6x/8.3x its FY2024E/FY2025E earnings. We retain our Buy recommendation on the stock with an unchanged PT of Rs. 450.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Strides Pharma Sciences - 27 -01-2023 - khan